11:24 AM EDT, 03/30/2026 (MT Newswires) -- Insmed ( INSM ) is seeing growing physician adoption of its Brinsupri therapy, with new survey data indicating expanding use and rising confidence in the drug's long-term potential, Morgan Stanley said in a report Monday. Brinsupri is a prescription drug developed by Insmed ( INSM ) to treat non-cystic fibrosis bronchiectasis. A survey...

10:56 AM EDT, 03/30/2026 (MT Newswires) -- Verisk Analytics' ( VRSK ) Q1 results are expected to be inline and the company will likely reiterate its fiscal 2026 guidance, RBC Capital Markets said. The brokerage said in a Friday note that Verisk's defensive business remains well-positioned amid macroeconomic uncertainty, while its $1.5 billion accelerated share repurchase agreement should provide downside...

MoonLake Immunotherapeutics ( MLTX ) shares are volatile on Monday as the company is reporting long-term results from its VELA-1 and VELA-2 Phase 3 clinical trials of sonelokimab in patients with hidradenitis suppurativa (HS). HS is a chronic, non-contagious inflammatory skin condition, often called acne inversa, that causes painful, recurring lumps or abscesses, primarily in sweat gland areas like the...

11:25 AM EDT, 03/30/2026 (MT Newswires) -- Alumis' ( ALMS ) recent phase 3 results for its psoriasis treatment envudeucitinib is very positive for the company, Oppenheimer said in a note emailed Monday. Envudeucitinib had similar efficacy as Johnson & Johnson's ( JNJ ) icotrokinra and Takeda Pharmaceutical's ( TAK ) zasocitinib, while the Alumis ( ALMS ) drug had...